Experimental combo targets tough breast cancer
NCT ID NCT03901469
Summary
This study tested whether combining two investigational drugs, ZEN003694 and talazoparib, could help control advanced triple-negative breast cancer in patients who had already tried other treatments. The trial involved 115 adults with cancer that had progressed despite prior therapy. Researchers aimed to find a safe, effective dose and see if the combination could shrink tumors or slow their growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affliated Hospital of Jining Medical University
Jining, Shandong, 272000, China
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Hunan Cancer Hospital
Changsha, Hunan, 410000, China
-
Institut Jules Bordet
Anderlecht, 1070, Belgium
-
MD Anderson
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
START Madrid
Madrid, 28050, Spain
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510289, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
Tennessee Oncology (Sarah Cannon)
Nashville, Tennessee, 37203, United States
-
The First Affiliated Hosptial of Bengbu Medical College
Bengbu, Anhui, 233000, China
-
The Second People's Hospital of Neijiang
Neijiang, Sichuan, 641100, China
-
Tianjing Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
-
UZ Leuven
Leuven, 3000, Belgium
-
University of Kansas Cancer Center
Westwood, Kansas, 66203, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.